87 results
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
without compromising the safety of the patient or interfering with the natural flow of fluids in the urinary tract. RTGel achieves this by:
increasing … a similar safety profile to that observed in our OPTIMA II and ATLAS trials, with treatment-emergent adverse events typically mild-to-moderate
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
for the improved efficacy of treatment of various types of urothelial and specialty cancers and urologic diseases without compromising the safety … in CR, the predicted median DOR is 40 months based on the Weibull Predicted Curve.
Our ENVISION trial demonstrated a similar safety profile
8-K
URGN
UroGen Pharma Ltd
13 Jun 24
Regulation FD Disclosure
10:51am
months based on the Weibull Predicted Curve.
The ENVISION trial demonstrated a similar safety profile to that observed in the OPTIMA II and ATLAS trials … of UGN-102 on the timeframe expected, or at all; the timing and success of clinical trials and potential safety or other complications encountered
8-K
EX-99.1
URGN
UroGen Pharma Ltd
13 Jun 24
Regulation FD Disclosure
10:51am
and potential safety or other complications encountered therein; results from prior or ongoing clinical trials may not be indicative of results … Response at 12 months Safety profile Non-surgical treatment characterized primarily by with potential to reduce mild to moderate AEs overall burden
8-K
EX-99.1
ywd4f2p74koq9
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
8-K
EX-99.1
f1em 5z10pbt541jh5
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
8-K
EX-99.1
q0nui3o21
4 Mar 24
Regulation FD Disclosure
7:00am
8-K
704pbbs4 3y9
1 Mar 24
Regulation FD Disclosure
7:00am
8-K
EX-99.1
2kewlz9oc3vocr0i4rgl
7 Feb 24
Regulation FD Disclosure
4:15pm
8-K
ecwbgcgudk0tdg8n48ej
17 Jan 24
Entry into a Material Definitive Agreement
4:16pm
8-K
lliklqa07x79wpfz791
2 Jan 24
Entry into a Material Definitive Agreement
8:04am
8-K
EX-99.1
xoii52z7
14 Nov 23
UroGen Pharma Reports Third Quarter 2023 Financial Results
12:00am
8-K
EX-99.1
j354e6hq
10 Aug 23
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
8:01am